Paricalcitol and Cardiorenal Outcome: From the IMPACT Study to Clinical Practice

Publisher： Karger

E-ISSN： 1421-9735|36|1|12-16

ISSN： 0253-5068

Source： Blood Purification, Vol.36, Iss.1, 2013-05, pp. : 12-16

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impact of Cardiorenal Anemia Syndrome on Short- and Long-Term Clinical Outcomes in Patients Hospitalized with Heart Failure

By  

Cardiorenal Medicine, Vol. 6, Iss. 4, 2016-04 ,pp. : 269-278

Karger

Access to resources Recommend Favorite

Cardiorenal Syndrome: The Clinical Cardiologists’ Perspective

By  

Cardiorenal Medicine, Vol. 1, Iss. 1, 2011-01 ,pp. : 13-22

Karger

Access to resources Recommend Favorite

Myocardial Stunning with Hemodialysis: Clinical Challenges of the Cardiorenal Patient

By  

Cardiorenal Medicine, Vol. 2, Iss. 2, 2012-03 ,pp. : 125-133

Karger

Access to resources Recommend Favorite

Inhibition of Parathyroid Hormone: A Dose Equivalency Study of Paricalcitol and Doxercalciferol

By  

American Journal of Nephrology, Vol. 25, Iss. 6, 2005-11 ,pp. : 591-595

Karger

Access to resources Recommend Favorite

Prevalence and Clinical Features of Patients with the Cardiorenal Syndrome Admitted to an Internal Medicine Ward

By  

Cardiorenal Medicine, Vol. 4, Iss. 2, 2014-05 ,pp. : 88-94

Karger

Access to resources Recommend Favorite